Special report: vaccines for the treatment of malignant melanoma
BlueCross BlueShield Association

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

The BlueCross BlueShield Association Technology Evaluation Center website (www.bcbs.com/tec) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website.

Citation

Authors' objectives
The specific objectives of this special report are informational in nature, as follows:

- to review the immunologic principles supporting the development of a melanoma vaccine;
- to review the various biologic approaches being taken to develop a melanoma vaccine, especially those that have resulted in phase III trials;
- to review the results of completed phase III trials of melanoma vaccines, and to summarize active and recently closed phase III trial protocols;
- to summarize and evaluate the evidence from phase I/II trials of those melanoma vaccines currently in phase III trials.

Project page URL
http://www.bcbs.com/blueresources/tec/contact-tec.html

Indexing Status
Subject indexing assigned by CRD

MeSH
Melanoma /drug therapy; Skin Neoplasms /drug therapy; Vaccination

Language Published
English

Country of organisation
United States

Address for correspondence
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321 Email: tec@bcbsa.com

AccessionNumber
32003000738

Date bibliographic record published
14/08/2003

Date abstract record published
14/08/2003

Health Technology Assessment (HTA) database
Copyright © 2017 BlueCross BlueShield Association (BCBS)